Unique ID issued by UMIN | UMIN000009641 |
---|---|
Receipt number | R000011309 |
Scientific Title | Evaluation of the influence of Vildagliptin on chorioretinal blood flow in patients with diabetic retinopathy |
Date of disclosure of the study information | 2012/12/31 |
Last modified on | 2013/12/27 16:59:07 |
Evaluation of the influence of Vildagliptin on chorioretinal blood flow in patients with diabetic retinopathy
Evaluation of the influence of Vildagliptin on chorioretinal blood flow in patients with diabetic retinopathy
Evaluation of the influence of Vildagliptin on chorioretinal blood flow in patients with diabetic retinopathy
Evaluation of the influence of Vildagliptin on chorioretinal blood flow in patients with diabetic retinopathy
Japan |
diabetic retinopathy
Endocrinology and Metabolism | Ophthalmology |
Others
NO
To compare the influences of vildagliptin or other oral hypoglycemic drugs on chorioretinal blood flow and other structural and functional visual outcomes in patients with type 2 diabetes and diabetic retinopathy.
Efficacy
Confirmatory
Pragmatic
Not applicable
chorioretinal blood flow
best corrected visual acuity, intraocular pressure, central retinal thickness, HbA1c, fasting blood glucose
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
YES
YES
Institution is not considered as adjustment factor.
NO
Pseudo-randomization
2
Treatment
Medicine |
Add each treatment for 6 months.
1) vildagliptin 50 or 100mg/day
2) other oral hypoglycemic drugs except anti-dipeptidyl peptidase-4 (DDP-4) inhibitor
20 | years-old | <= |
Not applicable |
Male and Female
1. Type 2 diabetic patients who meet the following requirements
1) Diabetic retinopathy requiring treatment
2) 6.9%<=HbA1c<=11.0%
3) No prior treatment using DDP-4 inhibitor
4) No change of oral hypoglycemic drugs for 3 months prior
2. Patients over 20 years-old.
3. Patients who have been informed and have understood the full explanation of this study, and have agreed and given prior written consent.
1. Type 1 diabetes, diabetic ketoacidosis or diabetic coma
2. Severe liver or kidney dysfunction
3. Severe infection or traumatic injury
4. In a perioperative period of major surgery
5. Anti-glutamic acid decarboxylase (GAD) antibody>=10U/ml
6. Poorly controlled hypertension; systolic blood pressure>=160mmHg or diastolic blood pressure>=100mmHg
7. Pregnant female, female with possibility of pregnancy and breast-feeding female
8. History of hypersensitivity to targeted medication
9. History of severe cardiovascular or cerebrovascular disease in 6 months
10. Any other factors that may disqualify the patient
50
1st name | |
Middle name | |
Last name | Takashi Kitaoka |
Nagasaki University Graduate School of Biomedical Sciences
Department of Ophthalmology & Visual Sciences
1-7-1 Sakamoto, Nagasaki city, Japan
095-819-7345
tkitaoka@nagasaki-u.ac.jp
1st name | |
Middle name | |
Last name | Yuki Maekawa |
Nagasaki University Graduate School of Biomedical Sciences
Department of Ophthalmology & Visual Sciences
1-7-1 Sakamoto, Nagasaki city, Japan
095-819-7345
maekaway@nagasaki-u.ac.jp
Nagasaki University Graduate School of Biomedical Sciences
Nagasaki University Graduate School of Biomedical Sciences
Self funding
Japan
1. Department of Metabolism/Diabetes and Clinical Nutrition, Nagasaki University Hospital
2. Department of Ophthalmology, Nagasaki University Hospital
NO
長崎大学病院(長崎県)/Nagasaki University Hospital
2012 | Year | 12 | Month | 31 | Day |
Unpublished
Preinitiation
2012 | Year | 12 | Month | 31 | Day |
2013 | Year | 01 | Month | 01 | Day |
2012 | Year | 12 | Month | 26 | Day |
2013 | Year | 12 | Month | 27 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011309
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |